The standard "short" course treatment for TB is isoniazid (along with pyridoxal phosphate to obviate peripheral neuropathy caused by isoniazid), rifampicin (also known as rifampin in the United States), pyrazinamide, and ethambutol for two months, then isoniazid and rifampicin alone for a further four months. The patient is considered to be free of living bacteria after six months (although there is still a relapse rate of up to 7%). For latent tuberculosis, the standard treatment is six to nine months of daily isoniazid alone or three months of weekly (12 doses total) of isoniazid/rifapentine combination. If the organism is known to be fully sensitive, then treatment is with isoniazid, rifampicin, and pyrazinamide for two months, followed by isoniazid and rifampicin for four months. Ethambutol need not be used.
- 1 Drugs
- 2 The standard regimen
- 3 Non-compliance
- 4 Adverse effects
- 5 Deviations from the standard regimen
- 6 Tuberculosis and other conditions
- 7 Drug-resistant tuberculosis
- 8 Treatment failure
- 9 Treatment relapse
- 10 Society and culture
- 11 Trial of therapy
- 12 Surgical treatment
- 13 Nutrition
- 14 Latent tuberculosis
- 15 Current research
- 16 See also
- 17 National and international guidelines
- 18 Bibliography
|First line tuberculosis drugs|
|Second line tuberculosis drugs|
All first-line anti-tuberculous drug names have a standard three-letter and a single-letter abbreviation:
- ethambutol is EMB or E,
- isoniazid is INH or H,
- pyrazinamide is PZA or Z,
- rifampicin is RMP or R,
- streptomycin is SM or S.
The US uses abbreviations and names that are not internationally recognised: rifampicin is called rifampin and abbreviated RIF; streptomycin is abbreviated STM. In the US only, streptomycin is no longer considered a first line drug by ATS/IDSA/CDC because of high rates of resistance. The WHO have made no such recommendation.
Drug regimens are similarly abbreviated in a standardised manner. The drugs are listed using their single letter abbreviations (in the order given above, which is roughly the order of introduction into clinical practice). A prefix denotes the number of months the treatment should be given for; a subscript denotes intermittent dosing (so 3 means three times a week) and no subscript means daily dosing. Most regimens have an initial high-intensity phase, followed by a continuation phase (also called a consolidation phase or eradication phase): the high-intensity phase is given first, then the continuation phase, the two phases divided by a slash.
means isoniazid, rifampicin, ethambutol, pyrazinamide daily for two months, followed by four months of isoniazid and rifampicin given three times a week.
These standard abbreviations are used in the rest of this article.
The second line drugs (WHO groups 2, 3 and 4) are only used to treat disease that is resistant to first line therapy (i.e., for extensively drug-resistant tuberculosis (XDR-TB) or multidrug-resistant tuberculosis (MDR-TB)). A drug may be classed as second-line instead of first-line for one of three possible reasons: it may be less effective than the first-line drugs (e.g., p-aminosalicylic acid); or, it may have toxic side-effects (e.g., cycloserine); or it may be effective, but unavailable in many developing countries (e.g., fluoroquinolones):
- aminoglycosides (WHO group 2): e.g., amikacin (AMK), kanamycin (KM);
- polypeptides (WHO group 2): e.g., capreomycin, viomycin, enviomycin;
- fluoroquinolones (WHO group 3): e.g., ciprofloxacin (CIP), levofloxacin, moxifloxacin (MXF);
- thioamides (WHO group 4): e.g. ethionamide, prothionamide
- cycloserine (WHO group 4)
- terizidone (WHO group 5)
Third-line drugs (WHO group 5) include drugs that may be useful, but have doubtful or unproven efficacy:
- macrolides: e.g., clarithromycin (CLR);
- linezolid (LZD);
- thioacetazone (T);
- vitamin D;
These drugs are listed here either because they are not very effective (e.g., clarithromycin) or because their efficacy has not been proven (e.g., linezolid, R207910). Rifabutin is effective, but is not included on the WHO list because for most developing countries, it is impractically expensive.
The standard regimen
Rationale and evidence for the standard regimen
- For treatment of lung tuberculosis, see main article pathophysiology
Tuberculosis has been treated with combination therapy for over fifty years. Drugs are not used singly (except in latent TB or chemoprophylaxis), and regimens that use only single drugs result in the rapid development of resistance and treatment failure. The rationale for using multiple drugs to treat TB are based on simple probability. The rate of spontaneous mutations that confer resistance to an individual drug are well known: 1 mutation for every 107 cell divisions for EMB, 1 for every 108 divisions for STM and INH, and 1 for every 1010 divisions for RMP.
Patients with extensive pulmonary TB have approximately 1012 bacteria in their body, and therefore will probably be harboring approximately 105 EMB-resistant bacteria, 104 STM-resistant bacteria, 104 INH-resistant bacteria and 10² RMP-resistant bacteria. Resistance mutations appear spontaneously and independently, so the chances of them harbouring a bacterium that is spontaneously resistant to both INH and RMP is 1 in 108 x 1 in 1010 = 1 in 1018, and the chances of them harbouring a bacterium that is spontaneously resistant to all four drugs is 1 in 1033. This is, of course, an oversimplification, but it is a useful way of explaining combination therapy.
There are other theoretical reasons for supporting combination therapy. The different drugs in the regimen have different modes of action. INH are bacteriocidal against replicating bacteria. EMB is bacteriostatic at low doses, but is used in TB treatment at higher, bactericidal doses. RMP is bacteriocidal and has a sterilizing effect. PZA is only weakly bactericidal, but is very effective against bacteria located in acidic environments, inside macrophages, or in areas of acute inflammation.
All TB regimens in use were 18 months or longer until the appearance of rifampicin. In 1953, the standard UK regimen was 3SPH/15PH or 3SPH/15SH2. Between 1965 and 1970, EMB replaced PAS. RMP began to be used to treat TB in 1968 and the BTS study in the 1970s showed that 2HRE/7HR was efficacious. In 1984, a BTS study showed that 2HRZ/4HR was efficacious, with a relapse rate of less than 3% after two years. In 1995, with the recognition that INH resistance was increasing, the British Thoracic Society recommended adding EMB or STM to the regimen: 2HREZ/4HR or 2SHRZ/4HR, which are the regimens currently recommended. The WHO also recommend a six-month continuation phase of HR if the patient is still culture positive after 2 months of treatment (approximately 15% of patients with fully sensitive TB) and for those patients who have extensive bilateral cavitation at the start of treatment.
Monitoring, DOTS, and DOTS-Plus
DOTS stands for "Directly Observed Treatment, Short-course" and is a major plank in the WHO Global Plan to Stop TB. The DOTS strategy focuses on five main points of action. These include government commitment to control TB, diagnosis based on sputum-smear microscopy tests done on patients who actively report TB symptoms, direct observation short-course chemotherapy treatments, a definite supply of drugs, and standardized reporting and recording of cases and treatment outcomes. The WHO advises that all TB patients should have at least the first two months of their therapy observed (and preferably the whole of it observed): this means an independent observer watching patients swallow their anti-TB therapy. The independent observer is often not a healthcare worker and may be a shopkeeper or a tribal elder or similar senior person within that society. DOTS is used with intermittent dosing (thrice weekly or 2HREZ/4HR3). Twice weekly dosing is effective but not recommended by the WHO, because there is no margin for error (accidentally omitting one dose per week results in once weekly dosing, which is ineffective).
Treatment with properly implemented DOTS has a success rate exceeding 95% and prevents the emergence of further multi-drug resistant strains of tuberculosis. Administering DOTS, decreases the possibilities of tuberculosis from recurring, resulting in a reduction in unsuccessful treatments. This is in part due to the fact that areas without the DOTS strategy generally provide lower standards of care. Areas with DOTS administration help lower the number of patients seeking help from other facilities where they are treated with unknown treatments resulting in unknown outcomes. However, if the DOTS program is not implemented or done so incorrectly positive results will be unlikely. In order for the program to work efficiently and accurately health providers must be fully engaged, links must be built between public and private practitioners, health services must be available to all, and global support is provided to countries trying to reach their TB prevention, and treatment aims. Some researchers suggest that, because the DOTS framework has been so successful in the treatment of tuberculosis in sub-Saharan Africa, DOTS should be expanded to non-communicable diseases such as diabetes mellitus, hypertension, and epilepsy.
The WHO extended the DOTS programme in 1998 to include the treatment of MDR-TB (called "DOTS-Plus"). Implementation of DOTS-Plus requires the capacity to perform drug-susceptibility testing (not routinely available even in developed countries) and the availability of second-line agents, in addition to all the requirements for DOTS. DOTS-Plus is therefore much more resource-expensive than DOTS, and requires much greater commitment from countries wishing to implement it. Resource limitations mean that the implementation of DOTS-Plus may lead inadvertently to the diversion of resources from existing DOTS programmes and a consequent decrease in the overall standard of care.
Monthly surveillance until cultures convert to negative is recommended for DOTS-Plus, but not for DOTS. If cultures are positive or symptoms do not resolve after three months of treatment, it is necessary to re-evaluate the patient for drug-resistant disease or nonadherence to drug regimen. If cultures do not convert to negative despite three months of therapy, some physicians may consider admitting the patient to hospital so as to closely monitor therapy.
Tuberculosis not affecting the lungs is called extra-pulmonary tuberculosis. Disease of the central nervous system is specifically excluded from this classification.
The UK and WHO recommendation is 2HREZ/4HR; the US recommendation is 2HREZ/7HR. There is good evidence from randomised-controlled trials to say that in tuberculous lymphadenitis and in TB of the spine, the six-month regimen is equivalent to the nine-month regimen; the US recommendation is therefore not supported by the evidence.
Up to 25% of patients with TB of the lymph nodes (TB lymphadenitis) will get worse on treatment before they get better and this usually happens in the first few months of treatment. A few weeks after starting treatment, lymph nodes often start to enlarge, and previously solid lymph nodes may soften and develop into tuberculous cervical lymphadenitis. This should not be interpreted as failure of therapy and is a common reason for patients (and their physicians) to panic unnecessarily. With patience, two to three months into treatment the lymph nodes start to shrink again and re-aspiration or re-biopsy of the lymph nodes is unnecessary: if repeat microbiological studies are ordered, they will show the continued presence of viable bacteria with the same sensitivity pattern, which further adds to the confusion: physicians inexperienced in the treatment of TB will then often add second-line drugs in the belief that the treatment is not working. In these situations, all that is required is re-assurance. Steroids may be useful in resolving the swelling, especially if it is painful, but they are unnecessary. Additional antibiotics are unnecessary and the treatment regimen does not need to be lengthened.
Tuberculosis of the central nervous system
Tuberculosis may affect the central nervous system (meninges, brain or spinal cord) in which case it is called TB meningitis, TB cerebritis, and TB myelitis respectively; the standard treatment is 12 months of drugs (2HREZ/10HR) and steroid are mandatory.
Diagnosis is difficult as CSF culture is positive in less than half of cases, and therefore a large proportion of cases are treated on the basis of clinical suspicion alone. PCR of CSF does not significantly improve the microbiology yield; culture remains the most sensitive method and a minimum of 5 ml (preferably 20 ml) of CSF should be sent for analysis. TB cerebritis (or TB of the brain) may require brain biopsy in order to make the diagnosis, because the CSF is commonly normal: this is not always available and even when it is, some clinicians would debate whether it is justified putting a patient through such an invasive and potentially dangerous procedure when a trial of anti-TB therapy may yield the same answer; probably the only justification for brain biopsy is when drug-resistant TB is suspected.
It is possible that shorter durations of therapy (e.g., six months) may be sufficient to treat TB meningitis, but no clinical trial has addressed this issue. The CSF of patients with treated TB meningitis is commonly abnormal even at 12 months; the rate of resolution of the abnormality bears no correlation with clinical progress or outcome, and is not an indication for extending or repeating treatment; repeated sampling of CSF by lumbar puncture to monitor treatment progress should therefore not be done.
Although TB meningitis and TB cerebritis are classified together, the experience of many clinicians is that their progression and response to treatment is not the same. TB meningitis usually responds well to treatment, but TB cerebritis may require prolonged treatment (up to two years) and the steroid course needed is often also prolonged (up to six months). Unlike TB meningitis, TB cerebritis often required repeated CT or MRI imaging of the brain to monitor progress.
The anti-TB drugs that are most useful for the treatment of Central nervous system TB are:
- INH (CSF penetration 100%)
- RMP (10–20%)
- EMB (25–50% inflamed meninges only)
- PZA (100%)
- STM (20% inflamed meninges only)
- LZD (20%)
- Cycloserine (80–100%)
- Ethionamide (100%)
- PAS (10–50%) (inflamed meninges only)
The use of steroids is routine in TB meningitis (see section below). There is evidence from one poorly designed trial that aspirin may be beneficial, but further work is required before this can be recommended routinely.
The usefulness of corticosteroids (e.g., prednisolone or dexamethasone) in the treatment of TB is proven for TB meningitis and TB pericarditis. The dose for TB meningitis is dexamethasone 8 to 12 mg daily tapered off over six weeks (for those who prefer more precise dosing should refer to Thwaites et al., 2004). The dose for pericarditis is prednisolone 60 mg daily tapered off over four to eight weeks.
Steroids may be of temporary benefit in pleurisy, extremely advanced TB, and TB in children:
- Pleurisy: prednisolone 20 to 40 mg daily tapered off over 4 to 8 weeks
- Extremely advanced TB: 40 to 60 mg daily tapered off over 4 to 8 weeks
- TB in children: 2 to 5 mg/kg/day for one week, 1 mg/kg/day the next week, then tapered off over 5 weeks
Steroids may be of benefit in peritonitis, miliary disease, tubercular osteomyelitis, TB osteomyelitis, laryngeal TB, lymphadenitis and genitourinary disease, but the evidence is scant and the routine use of steroids cannot be recommended. Steroid treatment in these patients should be considered on a case by case basis by the attending physician.
Patients who take their TB treatment in an irregular and unreliable way are at greatly increased risk of treatment failure, relapse and the development of drug-resistant TB strains.
There are variety of reasons why patients fail to take their medication. The symptoms of TB commonly resolve within a few weeks of starting TB treatment and many patients then lose motivation to continue taking their medication. Regular follow-up is important to check on compliance and to identify any problems patients are having with their medication. Patients need to be told of the importance of taking their tablets regularly, and the importance of completing treatment, because of the risk of relapse or drug-resistance developing otherwise.
One of the main complaints is the bulkiness of the tablets. The main offender is PZA (the tablets being the size of horse tablets). PZA syrup may be offered as a substitute, or if the size of the tablets is truly an issue and liquid preparations are not available, then PZA can be omitted altogether. If PZA is omitted, the patient should be warned that this results in a significant increase in the duration of treatment (details of regimens omitting PZA are given below).
The other complaint is that the medicines must be taken on an empty stomach to facilitate absorption. This can be difficult for patients to follow (for example, shift workers who take their meals at irregular times) and may mean the patient waking up an hour earlier than usual everyday just to take medication. The rules are actually less stringent than many physicians and pharmacists realise: the issue is that the absorption of RMP is reduced if taken with fat, but is unaffected by carbohydrate, protein, or antacids. So the patient can in fact have his or her medication with food as long as the meal does not contain fat or oils (e.g., a cup of black coffee or toast with jam and no butter). Taking the medicines with food also helps ease the nausea that many patients feel when taking the medicines on an empty stomach. The effect of food on the absorption of INH is not clear: two studies have shown reduced absorption with food but one study showed no difference. There is a small effect of food on the absorption of PZA and of EMB that is probably not clinically important.
It is possible to test urine for isoniazid and rifampicin levels in order to check for compliance. The interpretation of urine analysis is based on the fact that isoniazid has a longer half-life than rifampicin:
- urine positive for isoniazid and rifampicin patient probably fully compliant
- urine positive for isoniazid only patient has taken his medication in the last few days preceding the clinic appointment, but had not yet taken a dose that day.
- urine positive for rifampicin only patient has omitted to take his medication the preceding few days, but did take it just before coming to clinic.
- urine negative for both isoniazid and rifampicin patient has not taken either medicine for a number of days
In countries where doctors are unable to compel patients to take their treatment (e.g., the UK), some say that urine testing only results in unhelpful confrontations with patients and does not help increase compliance. In countries where legal measures can be taken to force patients to take their medication (e.g., the US), then urine testing can be a useful adjunct in assuring compliance.
RMP colours the urine and all bodily secretions (tears, sweat, etc.) an orange-pink colour and this can be a useful proxy if urine testing is not available (although this colour fades approximately six to eight hours after each dose).
In study on cases of extra-pulmonary TB (EPTB), researchers at the University of the Philippines Manila found that similarity of symptoms of EPTB to other diseases results to delayed identification of the disease and late provision of medication. This, ultimately contribute to increasing rates of mortality and incidence rates of EPTB.
The WHO recommends prescription of fixed-dose combination drugs, in order to improve adherence to treatment by reducing the number of tablets that need to be taken by people, and also possibly reducing prescribing errors. A Cochrane review published in 2016 found moderate quality evidence that "there is probably little or no difference in fixed-dose combination drugs compared to single-drug formulations".
For information on adverse effects of individual anti-TB drugs, please refer to the individual articles for each drug.
The relative incidence of major adverse effects has been carefully described:
- INH 0.49 per hundred patient months
- RMP 0.43
- EMB 0.07
- PZA 1.48
- All drugs 2.47
This works out to an 8.6% risk that any one patient will need to have his drug therapy changed during the course of standard short-course therapy (2HREZ/4HR). The people identified to be most at risk of major adverse side effects in this study were:
- age >60,
- HIV positive patients, and
It can be extremely difficult identifying which drug is responsible for which side effect, but the relative frequency of each is known. The offending drugs are given in decreasing order of frequency:
- Thrombocytopenia: Rifampicin (RMP)
- Neuropathy: Isoniazid (INH)
- Vertigo: Streptomycin (STM)
- Hepatitis: Pyrazinamide (PZA), RMP, INH
- Rash: PZA, RMP, Ethambutol (EMB)
The most frequent cause of neuropathy is INH. The peripheral neuropathy of INH is always a pure sensory neuropathy and finding a motor component to the peripheral neuropathy should always prompt a search for an alternative cause. Once a peripheral neuropathy has occurred, INH must be stopped and pyridoxine should be given at a dose of 50 mg thrice daily. Simply adding high dose pyridoxine to the regimen once neuropathy has occurred will not stop the neuropathy from progressing. Patients at risk of peripheral neuropathy from other causes (diabetes mellitus, alcoholism, renal failure, malnutrition, pregnancy, etc.) should all be given pyridoxine 10 mg daily at the start of treatment. Please refer to the entry on isoniazid for details on other neurological side effects of INH.
Rashes are most frequently due to PZA, but can occur with any of the TB drugs. Test dosing using the same regimen as detailed below for hepatitis may be necessary to determine which drug is responsible.
Itching RMP commonly causes itching without a rash in the first two weeks of treatment: treatment should not be stopped and the patient should be advised that the itch usually resolves on its own. Short courses of sedative antihistamines such as chlorpheniramine may be useful in alleviating the itch.
Fever during treatment can be due to a number of causes. It can occur as a natural effect of tuberculosis (in which case it should resolve within three weeks of starting treatment). Fever can be a result of drug resistance (but in that case the organism must be resistant to two or more of the drugs). Fever may be due to a superadded infection or additional diagnosis (patients with TB are not exempt from getting influenza and other illnesses during the course of treatment). In a few patients, the fever is due to drug allergy. The clinician must also consider the possibility that the diagnosis of TB is wrong. If the patient has been on treatment for more than two weeks and if the fever had initially settled and then come back, it is reasonable to stop all TB medication for 72 hours. If the fever persists despite stopping all TB medication, then the fever is not due to the drugs. If the fever disappears off treatment, then the drugs need to be tested individually to determine the cause. The same scheme as is used for test dosing for drug-induced hepatitis (described below) may be used. The drug most frequently implicated as causing a drug fever is RMP: details are given in the entry on rifampicin.
Drug-induced hepatitis, from TB treatment, has a mortality rate of around 5%. Three drugs can induce hepatitis: PZA, INH and RMP (in decreasing order of frequency). It is not possible to distinguish between these three causes based purely on signs and symptoms. Test dosing must be carried out to determine which drug is responsible (this is discussed in detail below).
Liver function tests (LFTs) should be checked at the start of treatment, but, if normal, need not be checked again; the patient need only be warned of the symptoms of hepatitis. Some clinicians insist on regular monitoring of LFT's while on treatment, and in this instance, tests need only be done two weeks after starting treatment and then every two months thereafter, unless any problems are detected.
Elevations in bilirubin must be expected with RMP treatment (RMP blocks bilirubin excretion) and usually resolve after 10 days (liver enzyme production increases to compensate). Isolated elevations in bilirubin can be safely ignored.
Elevations in liver transaminases (ALT and AST) are common in the first three weeks of treatment. If the patient is asymptomatic and the elevation is not excessive then no action need be taken; some experts suggest a cut-off of four times the upper limit of normal, but there is no evidence to support this particular number over and above any other number. Some experts consider that treatment should only be stopped if jaundice becomes clinically evident.
If clinically significant hepatitis occurs while on TB treatment, then all the drugs should be stopped until the liver transaminases return to normal. If the patient is so ill that TB treatment cannot be stopped, then STM and EMB should be given until the liver transaminases return to normal (these two drugs are not associated with hepatitis).
Fulminant hepatitis can occur in the course of TB treatment, but is fortunately rare; emergency liver transplantation may be necessary and deaths do occur.
Test dosing for drug-induced hepatitis
Drugs should be re-introduced individually. This cannot be done in an outpatient setting, and must be done under close observation. A nurse must be present to take patient's pulse and blood pressure at 15 minute intervals for a minimum of four hours after each test dose is given (most problems will occur within six hours of test dosing, (if they are going to occur). Patients can become very suddenly unwell and access to intensive care facilities must be available. The drugs should be given in this order:
- Day 1: INH at 1/3 or 1/4 dose
- Day 2: INH at 1/2 dose
- Day 3: INH at full dose
- Day 4: RMP at 1/3 or 1/4 dose
- Day 5: RMP at 1/2 dose
- Day 6: RMP at full dose
- Day 7: EMB at 1/3 or 1/4 dose
- Day 8: EMB at 1/2 dose
- Day 9: EMB at full dose
No more than one test dose per day should be given, and all other drugs should be stopped while test dosing is being done. So on day 4, for example, the patient only receives RMP and no other drugs are given. If the patient completes the nine days of test dosing, then it is reasonable to assume that PZA has caused the hepatitis and no PZA test dosing need be done.
The reason for using the order for testing drugs is because the two most important drugs for treating TB are INH and RMP, so these are tested first: PZA is the most likely drug to cause hepatitis and is also the drug that can be most easily omitted. EMB is useful when the sensitivity pattern of the TB organism are not known and can be omitted if the organism is known to be sensitive to INH. Regimens omitting each of the standard drugs are listed below.
The order in which the drugs are tested can be varied according to the following considerations:
- The most useful drugs (INH and RMP) should be tested first, because the absence of these drugs from a treatment regimen severely impairs its efficacy.
- The drugs most likely to be causing the reaction should be tested as late as possible (and possibly need not be tested at all). This avoids rechallenging patients with a drug to which they have already had a (possibly) dangerous adverse reaction.
A similar scheme may be used for other adverse effects (such as fever and rash), using similar principles.
Deviations from the standard regimen
There is evidence supporting some deviations from the standard regimen when treating pulmonary TB. Sputum culture positive patients who are smear negative at the start of treatment do well with only 4 months of treatment (this has not been validated for HIV-positive patients); and sputum culture negative patients do well on only 3 months of treatment (possibly because some of these patients never had TB at all). It is unwise to treat patients for only three or four months, but all TB physicians will have patients who stop their treatment early (for whatever reason), and it can be re-assuring to know that sometimes retreatment is unnecessary. Elderly patients who are already taking a large number of tablets may be offered 9HR, omitting PZA which is the bulkiest part of the regimen.
It may not always be necessary to treat with four drugs from the beginning. An example might be a close contact of a patient known to have a fully sensitive strain of tuberculosis: in this case, it is acceptable to use 2HRZ/4HR (omitting EMB and STM) in the expectation that their strain will be INH susceptible also. Indeed, this was previously the recommended standard regimen in many countries until the early 1990s, when isoniazid-resistance rates increased.
TB involving the brain or spinal cord (meningitis, encephalitis, etc.) is currently treated with 2HREZ/10HR (12 months of treatment in total), but there is no evidence to say that this is superior to 2HREZ/4HR, it is merely that no-one has been brave enough to do the clinic trial that answers the question if the short course is equivalent.
Regimens omitting isoniazid
Isoniazid resistance accounts 6.9% of isolates in the UK (2010). Worldwide, it is the most common type of resistance encountered, hence the current recommendation of using HREZ at the beginning of treatment until sensitivities are known. It is useful to know of current reported outbreaks (like the current outbreak of INH-resistant TB in London).
If patients are discovered to be infected with an isoniazid-resistant strain of TB having completed 2 months of HREZ, then they should be changed to RE for a further 10 months, and the same thing if the patient is intolerant to isoniazid (although 2REZ/7RE may be acceptable if the patient is well supervised). The US recommendation is 6RZE with the option of adding a quinolone such as moxifloxacin. The level of evidence for all these regimens is poor, and there is little to recommend one over the other.
Regimens omitting rifampicin
The UK prevalence of rifampicin (RMP) resistance is 1.4%. It is rare for TB strains to be resistant to RMP without also being resistant to INH, which means that rifampicin-resistance usually means resistance to INH as well (that is, MDR-TB). However, RMP intolerance is not uncommon (hepatitis or thrombocytopaenia being the most common reasons for stopping rifampicin). Of the first-line drugs, rifampicin is also the most expensive, and in the poorest countries, regimens omitting rifampicin are therefore often used. Rifampicin is the most potent sterilising drug available for the treatment of tuberculosis and all treatment regimens that omit rifampicin are significantly longer than the standard regimen.
The UK recommendation is 18HE or 12HEZ. The US recommendation is 9 to 12HEZ, with the option of adding a quinolone (for example, MXF).
Regimens omitting pyrazinamide
PZA is a common cause of rash, hepatitis and of painful arthralgia in the HREZ regimen, and can be safely stopped in those patients who are intolerant to it. Isolated PZA resistance is uncommon in M. tuberculosis, but M. bovis is innately resistant to PZA. PZA is not crucial to the treatment of fully sensitive TB, and its main value is in shortening the total treatment duration from nine months to six.
An alternative regimen is 2HRE/7HR, for which there is excellent clinical trial evidence. The 1994 US CDC guidelines for tuberculosis erroneously cite Slutkin as evidence that a nine-month regimen using only isoniazid and rifampicin is acceptable, but almost all of the patients in that study received ethambutol for the first two to three months (although this is not obvious from the abstract of that article). This mistake was rectified in the 2003 guidelines.
This regimen (2HRE/7HR) is the first-line regimen used to treat M. bovis, since M. bovis is intrinsically resistant to pyrazinamide.
Regimens omitting ethambutol
EMB intolerance or resistance is rare. If a patient is truly intolerant or is infected with TB that is resistant to EMB, then 2HRZ/4HR is an acceptable regimen. The main motivator for including EMB in the initial two months is because of increasing rates of INH resistance.
Tuberculosis and other conditions
People with alcoholic liver disease are at an increased risk of tuberculosis. The incidence of tuberculous peritonitis is particularly high in patients with cirrhosis of the liver.
There are broadly two categories of treatment: A. Cirrhotic patients with essentially normal baseline liver function tests( Childs A Cirrhosis) Such patients may be treated with standard 4 drug re-gime for 2 months followed by 2 drugs for remaining 4 months (total 6-month treatment). B. Cirrhotics patients altered baseline liver function tests (Childs B & C) According to 2010 WHO guidelines:depending on the severity of the disease and degree of decompensation,the following regimen can be used, by altering the num-ber of hepatotoxic drugs. One or two hepatotoxic drugs may be used in moderate-ly severe disease (e.g., Child B cirrhosis) whereas hepa-totoxic drugs are completely avoided in decompensated Child C cirrhosis. • Two hepatotoxic drugs - 9 months of Isoniazid, Rifampin and Etham-butol (until or unless isoniazid susceptibility is documented) - 2 months of Isoniazid, Rifampin, Ethambutol and Streptomycin followed by 6 months of Isoniazid and Rifampin • One hepatotoxic drug - 2 months of Isoniazid, Ethambutol & Strepto-mycin followed by 10 months of Isoniazid and Ethambutol • No hepatotoxic drugs - 18–24 months of Streptomycin, Ethambutol and Quinolones Patients with liver disease should have their liver function tests monitored regularly throughout TB treatment.
Drug-induced hepatitis is discussed in a separate section above.
Pregnancy itself is not a risk factor for TB.
Untreated TB in pregnancy is associated with an increased risk of miscarriage and major fetal abnormality, and treatment of pregnant women. The US guidelines recommend omitting PZA when treating TB in pregnancy; the UK and WHO guidelines make no such recommendation, and PZA is commonly used in pregnancy. There is extensive experience with the treatment of pregnant women with TB and no toxic effect of PZA in pregnancy has ever been found. High doses of RMP (much higher than used in humans) causes neural tube defects in animals, but no such effect has ever been found in humans. There may be an increased risk of hepatitis in pregnancy and during the puerperium. It is prudent to advise all women of child-bearing age to avoid getting pregnant until TB treatment is completed.
Aminoglycosides (STM, capreomycin, amikacin) should be used with caution in pregnancy, because they may cause deafness in the unborn child. The attending physician must weigh the benefits of treating the mother against the potential harm to the baby, and good outcomes have been reported in children whose mothers were treated with aminoglycosides. Experience in Peru shows that treatment for MDR-TB is not a reason to recommend termination of pregnancy, and that good outcomes are possible.
Patients with renal failure have a 10 to 30-fold increase in risk of getting TB. Patients with kidney disease who are being given immunosuppressive drugs or are being considered for transplant should be considered for treatment of latent tuberculosis if appropriate.
Aminoglycosides (STM, capreomycin and amikacin) should be avoided in patients with mild to severe kidney problems because of the increased risk of damage to the kidneys. If the use of aminoglycosides cannot be avoided (e.g., in treating drug-resistant TB) then serum levels must be closely monitored and the patient warned to report any side-effects (deafness in particular). If patient have end-stage renal failure and have no useful remaining kidney function, then aminoglycosides can be used, but only if drug levels can be easily measured (often only amikacin levels can be measured).
In mild renal impairment, no change needs to be made in dosing any of the other drugs routinely used in the treatment of TB. In severe renal insufficiency (GFR<30), the EMB dose should be halved (or avoided altogether). The PZA dose is 20 mg/kg/day (UK recommendation) or three-quarters the normal dose (US recommendation), but not much published evidence is available to support this.
When using 2HRZ/4HR in patients on dialysis, the drugs should be given daily during the initial high-intensity phase. In the continuation phase, the drugs should be given at the end of each haemodialysis session and no dose should be taken on non-dialysis days.
In patients with HIV, treatment for the HIV should be delayed until TB treatment is completed, if possible.
The current UK guidance (provided by the British HIV Association) is
- CD4 count over 200—delay treatment until the six months of TB treatment are complete.
- CD4 count 100 to 200—delay treatment until the initial two-month intensive phase of therapy is complete
- CD4 count less than 100—the situation is unclear and patients should be enrolled in clinical trials examining this question. There is evidence that if these patients are managed by a specialist in both TB and HIV then outcomes are not compromised for either disease.
If HIV treatment has to be started while a patient is still on TB treatment, then the advice of a specialist HIV pharmacist should be sought. In general, there is no significant interactions with the NRTI's. Nevirapine should not be used with rifampicin. Efavirenz may be used, but dose used depends on the patient's weight (600 mg daily if weight less than 50 kg; 800 mg daily if weight greater than 50 kg). Efavirenz levels should be checked early after starting treatment (unfortunately, this is not a service routinely offered in the US, but is readily available in the UK). The protease inhibitors should be avoided if at all possible: patients on rifamycins and protease inhibitors have an increased risk of treatment failure or relapse.
According to Caprisa 003 (SAPiT) Study the mortality in patients who were started on Anti-retorvirals during TB treatment was 56% lower than those started after TB treatment was completed.(Hazard Ratio:0.44 (95% CI: 0.25 to 0.79); p=0.003.
INH may be associated with an increased risk of seizures. Pyridoxine 10 mg daily should be given to all epileptics taking INH. There is no evidence that INH causes seizures in patients who are not epileptic.
TB treatment involves numerous drug interactions with anti-epileptic drugs and serum drug levels should be closely monitored. There are serious interactions between rifampicin and carbamazepine, rifampicin and phenytoin, and rifampicin and sodium valproate. The advice of a pharmacist should always be sought.
Multi-drug resistant tuberculosis (MDR-TB) is defined as TB that is resistant at least to INH and RMP. Isolates that are multi-resistant to any other combination of anti-TB drugs but not to INH and RMP are not classed as MDR-TB.
As of Oct 2006, "Extensively drug-resistant tuberculosis" (XDR-TB) is defined as MDR-TB that is resistant to quinolones and also to any one of kanamycin, capreomycin, or amikacin. The old case definition of XDR-TB is MDR-TB that is also resistant to three or more of the six classes of second-line drugs. This definition should no longer be used, but is included here because many older publications refer to it.
The principles of treatment for MDR-TB and for XDR-TB are the same. The main difference is that XDR-TB is associated with a much higher mortality rate than MDR-TB, because of a reduced number of effective treatment options. The epidemiology of XDR-TB is currently not well studied, but it is believed that XDR-TB does not transmit easily in healthy populations, but is capable of causing epidemics in populations which are already stricken by HIV and therefore more susceptible to TB infection.
Epidemiology of drug-resistant TB
A 1997 survey of 35 countries found rates above 2% in about a third of the countries surveyed. The highest rates were in the former USSR, the Baltic states, Argentina, India and China, and was associated with poor or failing national Tuberculosis Control programmes. Likewise, the appearance of high rates of MDR-TB in New York city the early 1990s was associated with the dismantling of public health programmes by the Reagan administration.
Paul Farmer also argues that the more expensive a treatment is, the harder it is for poor countries to get this treatment. The issue of human rights is mentioned here. It was mentioned in this article that Africa is at the end of the receiving line of treatments because they lack the 'concept of time' which he described as the schedule of administration and this concept hinders their reception of treatment.
MDR-TB can develop in the course of the treatment of fully sensitive TB and this is always the result of patients missing doses or failing to complete a course of treatment.
Thankfully, MDR-TB strains appear to be less fit and less transmissible. It has been known of many years that INH-resistant TB is less virulent in guinea pigs, and the epidemiological evidence is that MDR strains of TB do not dominate naturally. A study in Los Angeles found that only 6% of cases of MDR-TB were clustered. This should not be a cause for complacency: it must be remembered that MDR-TB has a mortality rate comparable to lung cancer. It must also be remembered that people who have weakened immune systems (because of diseases such as HIV or because of drugs) are more susceptible to catching TB.
Children represent a susceptible population with increasing rates of MDR and XDR-TB. Since diagnosis in pediatric patients is difficult, large number of cases are not properly reported. Cases of pediatric XDR-TB have been reported in most countries including the United States.
There is currently an epidemic of XDR-TB South Africa. The outbreak was first reported as a cluster of 53 patients in a rural hospital in KwaZulu-Natal of whom 52 died. What was particularly worrying was that the mean survival from sputum specimen collection to death was only 16 days and that the majority of patients had never previously received treatment for tuberculosis. This is the epidemic for which the acronym XDR-TB was first used, although TB strains that fulfil the current definition have been identified retrospectively, this was the largest group of linked cases ever found. Since the initial report in September 2006, cases have now been reported in most provinces in South Africa. As of 16 March 2007, there were 314 cases reported, with 215 deaths. It is clear that the spread of this strain of TB is closely associated with a high prevalence of HIV and poor infection control; in other countries where XDR-TB strains have arisen, drug-resistance has arisen from mismanagement of cases or poor patient compliance with drug treatment instead of being transmitted from person to person. This strain of TB does not respond to any of the drugs currently available in South Africa for first- or second-line treatment. It is now clear that the problem has been around for much longer than health department officials have suggested, and is far more extensive. By 23 November 2006, 303 cases of XDR-TB had been reported, of which 263 were in KwaZulu-Natal. Serious thought has been put to isolation procedures that may deny some patients their human rights, but which may be necessary to prevent further spread of this strain of TB.
Treatment of MDR-TB
The treatment and prognosis of MDR-TB are much more akin to that for cancer than to that for infection. It has a mortality rate of up to 80%, which depends on a number of factors, including
- How many drugs the organism is resistant to (the fewer the better),
- How many drugs the patient is given (patients treated with five or more drugs do better),
- Whether an injectable drug is given or not (it should be given for the first three months at least),
- The expertise and experience of the physician responsible,
- How co-operative the patient is with treatment (treatment is arduous and long, and requires persistence and determination on the part of the patient),
- Whether the patient is HIV positive or not (HIV co-infection is associated with an increased mortality).
Treatment courses are a minimum of 18 months and may last years; it may require surgery, though death rates remain high despite optimal treatment. That said, good outcomes are still possible. Treatment courses that are at least 18 months long and which have a directly observed component can increase cure rates to 69%.
The treatment of MDR-TB must be undertaken by a physician experienced in the treatment of MDR-TB. Mortality and morbidity in patients treated in non-specialist centres is significantly elevated compared to those patients treated in specialist centres.
In addition to the obvious risks (i.e., known exposure to a patient with MDR-TB), risk factors for MDR-TB include male sex, HIV infection, previous incarceration, failed TB treatment, failure to respond to standard TB treatment, and relapse following standard TB treatment.
A large proportion of people suffering from MDR-TB are unable to access treatment due to what Paul Farmer describes as an "Outcome Gap". The majority of people struck with MDR-TB live in "resource-poor settings" and are denied treatment because international organizations have refused to make technologies available to countries who cannot afford to pay for treatment, the reason being that second line drugs are to expensive therefore treatment methods for MDR-TB are not sustainable in impoverished nations. Paul Farmer argues that this is social injustice and we cannot allow people to die simply because they are faced with circumstances where they cannot afford "effective therapy".
Treatment of MDR-TB must be done on the basis of sensitivity testing: it is impossible to treat such patients without this information. If treating a patient with suspected MDR-TB, the patient should be started on SHREZ+MXF+cycloserine pending the result of laboratory sensitivity testing.
A gene probe for rpoB is available in some countries and this serves as a useful marker for MDR-TB, because isolated RMP resistance is rare (except when patients have a history of being treated with rifampicin alone). If the results of a gene probe (rpoB) are known to be positive, then it is reasonable to omit RMP and to use SHEZ+MXF+cycloserine. The reason for maintaining the patient on INH despite the suspicion of MDR-TB is that INH is so potent in treating TB that it is foolish to omit it until there is microbiological proof that it is ineffective.
When sensitivities are known and the isolate is confirmed as resistant to both INH and RMP, five drugs should be chosen in the following order (based on known sensitivities):
- an aminoglycoside (e.g., amikacin, kanamycin) or polypeptide antibiotic (e.g., capreomycin)
- a fluoroquinolones: moxifloxacin is preferred (ciprofloxacin should no longer be used);
- a thioamide: prothionamide or ethionamide
- a macrolide: e.g., clarithromycin
- high-dose INH (if low-level resistance)
- meropenem and clavulanic acid
Drugs are placed nearer the top of the list because they are more effective and less toxic; drugs are placed nearer the bottom of the list because they are less effective or more toxic, or more difficult to obtain.
Resistance to one drug within a class generally means resistance to all drugs within that class, but a notable exception is rifabutin: rifampicin-resistance does not always mean rifabutin-resistance and the laboratory should be asked to test for it. It is only possible to use one drug within each drug class. If it is difficult finding five drugs to treat then the clinician can request that high level INH-resistance be looked for. If the strain has only low level INH-resistance (resistance at 1.0 mg/l INH, but sensitive at 0.2 mg/l INH), then high dose INH can be used as part of the regimen. When counting drugs, PZA and interferon count as zero; that is to say, when adding PZA to a four drug regimen, you must still choose another drug to make five. It is not possible to use more than one injectable (STM, capreomycin or amikacin), because the toxic effect of these drugs is additive: if possible, the aminoglycoside should be given daily for a minimum of three months (and perhaps thrice weekly thereafter). Ciprofloxacin should not be used in the treatment of tuberculosis if other fluoroquinolones are available.[needs update]
There is no intermittent regimen validated for use in MDR-TB, but clinical experience is that giving injectable drugs for five days a week (because there is no-one available to give the drug at weekends) does not seem to result in inferior results. Directly observed therapy certainly helps to improve outcomes in MDR-TB and should be considered an integral part of the treatment of MDR-TB.
Response to treatment must be obtained by repeated sputum cultures (monthly if possible). Treatment for MDR-TB must be given for a minimum of 18 months and cannot be stopped until the patient has been culture-negative for a minimum of nine months. It is not unusual for patients with MDR-TB to be on treatment for two years or more.
Patients with MDR-TB should be isolated in negative-pressure rooms, if possible. Patients with MDR-TB should not be accommodated on the same ward as immunosuppressed patients (HIV infected patients, or patients on immunosuppressive drugs). Careful monitoring of compliance with treatment is crucial to the management of MDR-TB (and some physicians insist on hospitalisation if only for this reason). Some physicians will insist that these patients are isolated until their sputum is smear negative, or even culture negative (which may take many months, or even years). Keeping these patients in hospital for weeks (or months) on end may be a practical or physical impossibility and the final decision depends on the clinical judgement of the physician treating that patient. The attending physician should make full use of therapeutic drug monitoring (particularly of the aminoglycosides) both to monitor compliance and to avoid toxic effects.
Some supplements may be useful as adjuncts in the treatment of tuberculosis, but for the purposes of counting drugs for MDR-TB, they count as zero (if you already have four drugs in the regimen, it may be beneficial to add arginine or vitamin D or both, but you still need another drug to make five).
The drugs listed below have been used in desperation and it is uncertain whether they are effective at all. They are used when it is not possible to find five drugs from the list above.
On December 28, 2012 the U.S. Food and Drug Administration (FDA) approved bedaquiline (marketed as Sirturo by Johnson & Johnson) to treat multi-drug resistant tuberculosis, the first new treatment in 40 years. Sirturo is to be used in a combination therapy for patients who have failed standard treatment and have no other options. Sirturo is an adenosine triphosphate synthase (ATP synthase) inhibitor.
The follow drug is experimental compounds that are not commercially available, but which may be obtained from the manufacturer as part of a clinical trial or on a compassionate basis. Their efficacy and safety are unknown:
Patients who fail treatment must be distinguished from patients who relapse. Patients who responded to treatment and appeared to be cured after completing a course of TB treatment are not classed as treatment failures, but as relapses and are discussed in a separate section below.
Patients are said to have failed treatment if they
- fail to respond to treatment (cough and sputum production persisting throughout the whole of treatment), or
- only experience a transient response to treatment (the patient gets better at first, but then get worse again, all the while on treatment).
It is very uncommon for patients not to respond to TB treatment at all (even transiently), because this implies resistance at base-line to all of the drugs in the regimen. Patients who fail to get any response at all while on treatment should first of all be questioned very closely about whether or not they have been taking their medicines, and perhaps even be admitted to hospital to be observed taking their treatment. Blood or urine samples may be taken to check for malabsorption of TB drugs. If it can be shown that they are fully compliant with their medication, then the probability that they have another diagnosis (perhaps in addition to the diagnosis of TB) is very high. These patients should have their diagnosis carefully reviewed and specimens obtained for TB culture and sensitivity testing. Patients who get better and then get worse again should likewise be question very closely about adherence to treatment. If adherence is confirmed then they should be investigated for resistant TB (including MDR-TB), even if a specimen has already been obtained for microbiology before commencing treatment.
Prescription or dispensing errors will account for a proportion of patients who fail to respond to treatment. Immune defects are a rare cause of non-response. In a tiny proportion of patients, treatment failure is a reflection of extreme biological variation and no cause is found.
|This section does not cite any sources. (May 2011) (Learn how and when to remove this template message)|
Patients are said to relapse if they improve while on treatment, but become ill again after stopping treatment. Patients who experience only a transient improvement while on treatment, or who never respond to treatment are said to have failed treatment and are discussed above.
There is a small relapse rate associated with all treatment regimens, even if the treatment has been taken religiously with 100% compliance (the standard regimen 2HREZ/4HR has a relapse rate of 2 to 3% under trial conditions). The majority of relapses occur within 6 months of finishing treatment. Patients who are more likely to relapse are those who took their medication in an unreliable and irregular fashion.
The probability of resistance is higher in those patients who relapse and every effort must be made to obtain a specimen that can be cultured for sensitivities. That said, most patients who relapse do so with a fully sensitive strain and it is possible that these patients have not relapsed, but have instead been re-infected; these patients can be re-treated with the same regimen as before (no drugs need to be added to the regimen and the duration need not be any longer).
The WHO recommends a regimen of 2SHREZ/6HRE when microbiology is not available (the majority of countries where TB is highly endemic). This regimen was designed to provide optimal treatment for fully sensitive TB (the most common finding in patients who have relapsed) as well as to cover the possibility of INH-resistant TB (the most common form of resistance found).
Because of the lifelong risk of relapse, all patients should be warned of the symptoms of TB relapse upon finishing treatment and given strict instructions to return to their doctor if symptoms recur.
Society and culture
As of 2010, India has more reported cases of TB than any other country. This is in part due to severe mismanagement of diagnosis and treatment of TB within the private health care sector of India that serves about 50% of the population. There are therefore calls for the private sector to engage in the public Revised National Tuberculosis Control Program that has proved effective in reducing TB amongst the patients receiving health care through the government. Additionally, a study by Maurya et al. conducted in 2013 shows evidence that there is a burden of multidrug-resistant tuberculosis in India and change is needed for testing, surveillance, monitoring and management.
Trial of therapy
In areas where TB is highly endemic, it is not unusual to encounter patient with a fever, but in whom no source of infection is found. The physician may then, after extensive investigation has excluded all other diseases, resort to a trial of TB treatment. The regimen used is HEZ for a minimum of three weeks; RMP and STM are omitted from the regimen because they are broad spectrum antibiotics, whereas the other three first-line drugs treat only mycobacterial infection. Resolution of the fever after three weeks of treatment is good evidence for occult TB and the patient should then be changed to conventional TB treatment (2HREZ/4HR). If the fever does not resolve after three weeks of treatment then it is reasonable to conclude that the patient has another cause for his fever.
This approach is not recommended by the WHO and most national guidelines.
Surgery has played an important part in the management of tuberculosis since the 1940s.
Historical surgical management
The first successful treatments for tuberculosis were all surgical. They were based on the observation that healed tuberculous cavities were all closed. Surgical management was therefore directed at closing open cavities in order to encourage healing. These procedures were all used in the pre-antibiotic era. There exists a myth that surgeons believed that the purpose was to deprive the organism of oxygen: it was however well known that the organism survives anaerobic conditions. Although these procedures may be considered barbaric by 21st century's standards, it must be remembered that these treatments represented a potential cure for a disease that at the time had a mortality at least as bad as lung cancer in 2000s.
- Recurrent or persistent pneumothorax
- The simplest and earliest procedure was to introduce air into the pleural space so as to collapse the affected lung and therefore the open cavity. There was always spontaneous resolution of the pneumothorax and the procedure had to be repeated every few weeks.
- Phrenic nerve crush
- The phrenic nerve (which supplies the diaphragm) was cut or crushed so as to permanently paralyse the diaphragm on that side. The paralysed diaphragm would then rise up and the lung on that side would collapse, thus closing the cavity.
- When the cavity was located in the apex of the lung, thoracoplasty could be performed. Six to eight ribs were broken and pushed into the thoracic cavity to collapse the lung beneath. This was a disfiguring operation, but it avoided the need for repeated procedures.
- Plombage reduced the need for a disfiguring operation. It involved inserting porcelain balls into the thoracic cavity to collapse the lung underneath.
Surgical resection of infected lung was not possible in the 1940s and 1950s, because the science of anaesthesia at the time was not sufficiently advanced to permit surgery on the lungs of an anaesthetised patient.
Modern surgical management
In modern times, the surgical treatment of tuberculosis is confined to the management of multi-drug resistant TB. A patient with MDR-TB who remains culture positive after many months of treatment may be referred for lobectomy or pneumonectomy with the aim of cutting out the infected tissue. The optimal timing for surgery has not been defined, and surgery still confers significant morbidity. The centre with the largest experience in the US is the National Jewish Medical and Research Center in Denver, Colorado. From 1983 to 2000, they performed 180 operations in 172 patients; of these, 98 were lobectomies, and 82 were pneumonectomies. They report a 3.3% operative mortality, with an additional 6.8% dying following the operation; 12% experienced significant morbidity (particularly extreme breathlessness). Of 91 patients who were culture positive before surgery, only 4 were culture positive after surgery.
Some complications of treated tuberculosis like recurrent hemoptysis, destroyed or bronchiectaic lungs and empyema (a collection of pus in the pleural cavity) are also amenable to surgical therapy.
In extrapulmonary TB, surgery is often needed to make a diagnosis (rather than to effect a cure): surgical excision of lymph nodes, drainage of abscesses, tissue biopsy, etc. are all examples of this. Samples taken for TB culture should be sent to the laboratory in a sterile pot with no additive (not even water or saline) and must arrive in the laboratory as soon as possible. Where facilities for liquid culture are available, specimens from sterile sites may be inoculated directly following the procedure: this may improve the yield. In spinal TB, surgery is indicated for spinal instability (when there is extensive bony destriction) or when the spinal cord is threatened. Therapeutic drainage of tuberculous abscesses or collections is not routinely indicated and will resolve with adequate treatment. In TB meningitis, hydrocephalus is a potential complication and may necessitate the insertion of a ventricular shunt or drain.
It is well known that malnutrition is a strong risk factor for becoming unwell with TB, that TB is itself a risk factor for malnutrition, and that malnourished patients with TB (BMI less than 18.5) are at an increased risk of death even with appropriate antibiotic therapy. Knowledge about the association between malnutrition and TB is prevalent in some cultures, and may reduce diagnostic delay and improve adherence to treatment.
Vitamin D and tuberculosis epidemiology
Vitamin D deficiency is a risk factor for tuberculosis, and vitamin D deficiency appears to impair the body's ability to fight tuberculosis, but there is no clinical evidence to show that treating vitamin D deficiency prevents tuberculosis, although the available evidence is that it ought to. Reduced levels of vitamin D may explain the increased susceptibility of African-Americans to tuberculosis, and may also explain why phototherapy is effective for lupus vulgaris (tuberculosis of the skin) (a finding which won Niels Finsen the Nobel Prize in 1903), because skin exposed to sunlight naturally produces more vitamin D.
Genetic differences in the vitamin D receptor in West African, Gujarati and Chinese populations have been noted to affect susceptibility to tuberculosis, but there is no data available in any population that shows vitamin D supplementation (that is, giving extra vitamin D to people with normal vitamin D levels) has any effect on susceptibility to TB.
Vitamin D and tuberculosis treatment
Giving vitamin D to TB patients who are vitamin D deficient may be beneficial in a proportion of patients. When taken as a group, vitamin D supppliementation appears to have no benefit when using sputum culture conversion as an endpoint, and giving vitamin D supplements to TB patients who have normal vitamin D levels does not provide any benefit from the point of view of TB. In a subset of patients with the tt genotype of the TaqI vitamin D receptor and who are vitamin D deficient, vitamin D supplementation appears to hasten sputum culture conversion. There are no studies of vitamin D using the gold standard outcome of relapse, so the true benefit of vitamin D is not at present known.
It was noted as early as the mid-19th century that cod liver oil (which is rich in vitamin D) improved patients with tuberculosis, and the mechanism for this is probably an enhancement of immune responses to tuberculosis.
The addition of vitamin D appears to enhance the ability of monocytes and macrophages to kill M. tuberculosis in vitro as well as ameliorating potentially harmful effects of the human immune system.
The treatment of latent tuberculosis infection (LTBI) is essential to controlling and eliminating TB by reducing the risk that TB infection will progress to disease.
The terms "preventive therapy" and "chemoprophylaxis" have been used for decades and are preferred in the UK because it involves giving medication to people who have no active disease and are currently well, the reason for treatment is primarily to prevent people from becoming unwell. The term "latent tuberculosis treatment" is preferred in the US because the medication does not actually prevent infection: it prevents an existing silent infection from becoming active. The feeling in the US is that the term "treatment of LTBI" promotes wider implementation by convincing people that they are receiving treatment for disease. There are no convincing reasons to prefer one term over the other.
It is essential that assessment to rule out active TB is carried out before treatment for LTBI is started. To give LTBI treatment to someone with active TB is a serious error: the TB will not be adequately treated and there is a risk of developing drug-resistant strains of TB.
There are several treatment regimens available:
- 9H—Isoniazid for 9 months is the gold standard and is 93% effective.
- 6H—Isoniazid for 6 months might be adopted by a local TB program based on cost-effectiveness and patient compliance. This is the regimen currently recommended in the UK for routine use. The US guidance exclude this regimen from use in children or persons with radiographic evidence of prior tuberculosis (old fibrotic lesions). (69% effective)
- 6 to 9H2—A twice-weekly regimen for the above two treatment regimens is an alternative if administered under Directly observed therapy (DOT).
- 4R—Rifampicin for 4 months is an alternative for those who are unable to take isoniazid or who have had known exposure to isoniazid-resistant TB.
- 3HR—Isoniazid and rifampicin may be given for 3 months.
- 2RZ—The 2-month regimen of rifampicin and pyrazinamide is no longer recommended for treatment of LTBI because of the greatly increased risk of drug-induced hepatitis and death.
- 3RPT/INH - 3-month (12-dose) regimen of weekly rifapentine and isoniazid.
Evidence for treatment effectiveness:
A 2000 Cochran review containing 11 double-blinded, randomized control trials and 73,375 patients examined six and 12 month courses of isoniazid (INH) for treatment of latent tuberculosis. HIV positive and patients currently or previously treated for tuberculosis were excluded. The main result was a relative risk (RR) of 0.40 (95% confidence interval (CI) 0.31 to 0.52) for development of active tuberculosis over two years or longer for patients treated with INH, with no significant difference between treatment courses of six or 12 months (RR 0.44, 95% CI 0.27 to 0.73 for six months, and 0.38, 95% CI 0.28 to 0.50 for 12 months). A recent systematic review published by the Cochrane Collaboration, compared Rifamycins (monotheraphy and combination therapy) to INH monotheraphy as an alternative in preventing active TB in HIV negative populations. The evidence suggested that shorter Rifampicin regimes (3 or 4 months) had higher treatment completion rates and fewer adverse events when compared to INH. However, the overall quality of evidence as per GRADE criteria was low to moderate. Another meta-analysis came to a similar conclusion, namely that rifamycin-containing regimens taken for 3 months or longer had a better profile in preventing TB reactivation.
There is some evidence from animal and clinical studies that suggests that moxifloxacin-containing regimens as short as four months may be as effective as six months of conventional therapy. Bayer is currently running a Phase II clinical trial in collaboration with the TB Alliance to evaluate shorter treatment regimens for TB; encouragingly, Bayer have also promised that if the trials are successful, Bayer will make moxifloxacin affordable and accessible in countries that need it.
- ATC code J04 Drugs for treatment of TB
- Mantoux test
- Heaf test
- TB Alliance
- Tuberculosis treatment in Colorado Springs (historical)
National and international guidelines
- ^ World Health Organisation (2003). "Treatment of Tuberculosis: Guidelines for National Programmes" (PDF).
- ^ Tuberculosis Coalition for Technical Assistance (The Hague) (2006). "International Standards for Tuberculosis Care".
- ^ National Institute for Health and Clinical Excellence (UK) (2006). "Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control".
- ^ American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America (2003). "Treatment of Tuberculosis" (PDF).
- ^ Centers for Disease Control and Prevention (2000). "Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection" (PDF). American Thoracic Society. 161 (4 Pt 2): S221–47. doi:10.1164/ajrccm.161.supplement_3.ats600. PMID 10764341.
- Sterling T. R., Villarino M. E., Borisov , Chaisson R. E. (2011). "Three months of rifapentine and isoniazid for latent tuberculosis infection". New England Journal of Medicine. 365 (23): 2155–2166. doi:10.1056/nejmoa1104875.
- World Health Organization. Guidelines on the management of latent tuberculosis infection. WHO/HTM/TB/2015.01. Geneva: World Health Organization; 2015.
- a) ftp://ftp.cdc.gov/pub/nchstp/tb/...web/.../3.0%20Drug%20Resistance.ppt,b) http://harrisons.unboundmedicine.com/harrisons/ub/view/Harrisons-Manual-of-Medicine/148139/all/Antituberculosis_Treatment_Regimens_%5Btable%5D
- Multidrug and extensively drug-resistant TB (M/XDR-TB) Drugs Used in the Treatment of Tuberculosis
- "Streptomycin Treatment of Pulmonary Tuberculosis: A Medical Research Council Investigation". British Medical Journal. 2 (4582): 769–82. October 1948. doi:10.1136/bmj.2.4582.769. PMC . PMID 18890300.
- Wang JY, Hsueh PR, Jan IS, et al. (October 2006). "Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas". Thorax. 61 (10): 903–08. doi:10.1136/thx.2005.056887. PMC . PMID 16809417.
- David HL (November 1970). "Probability Distribution of Drug-Resistant Mutants in Unselected Populations of Mycobacterium tuberculosis". Applied Microbiology. 20 (5): 810–14. PMC . PMID 4991927.
- British Thoracic Society (October 1984). "A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond.". British Journal of Diseases of the Chest. 78 (4): 330–36. doi:10.1016/0007-0971(84)90165-7. PMID 6386028.
- Ormerod LP, Horsfield N; Horsfield (July 1987). "Short-course antituberculous chemotherapy for pulmonary and pleural disease: 5 years' experience in clinical practice". British Journal of Diseases of the Chest. 81 (3): 268–71. doi:10.1016/0007-0971(87)90160-4. PMID 3663498.
- East AFrican/British Medical Research Councils (1986). "Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study". Tubercle. 67 (1): 5–15. PMID 3521015.
- Elzinga G, Raviglione MC, Maher D; Raviglione; Maher (March 2004). "Scale up: meeting targets in global tuberculosis control". Lancet. 363 (9411): 814–19. doi:10.1016/S0140-6736(04)15698-5. PMID 15016493.
- Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA; Catlin; Peterson; Judson; Sbarbaro (March 1990). "A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen". Annals of Internal Medicine. 112 (6): 407–15. doi:10.7326/0003-4819-76-3-112-6-407. PMID 2106816.
- Dye C, Watt CJ, Bleed DM, Williams BG; Watt; Bleed; Williams (2003). "What is the limit to case detection under the DOTS strategy for tuberculosis control?". Tuberculosis. 83 (1–3): 35–43. doi:10.1016/S1472-9792(02)00056-2. PMID 12758187.
- Grange JM; Zumla A (June 2002). "The global emergency of tuberculosis: what is the cause?". The Journal of the Royal Society for the Promotion of Health. 122 (2): 78–81. doi:10.1177/146642400212200206. PMID 12134771.
- Harries AD, Jahn A, Zachariah R, Enarson D; Jahn; Zachariah; Enarson (June 2008). "Adapting the DOTS framework for tuberculosis control to the management of non-communicable diseases in sub-Saharan Africa". PLoS Medicine. 5 (6): e124. doi:10.1371/journal.pmed.0050124. PMC . PMID 18547138.
- Iseman MD (November 1998). "MDR-TB and the developing world--a problem no longer to be ignored: the WHO announces 'DOTS Plus' strategy". The International Journal of Tuberculosis and Lung Disease. 2 (11): 867. PMID 9848604.
- Sterling TR, Lehmann HP, Frieden TR; Lehmann; Frieden (March 2003). "Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis". BMJ. 326 (7389): 574. doi:10.1136/bmj.326.7389.574. PMC . PMID 12637401.
- Campbell IA, Ormerod LP, Friend JA, Jenkins PA, Prescott RJ; Ormerod; Friend; Jenkins; Prescott (November 1993). "Six months versus nine months chemotherapy for tuberculosis of lymph nodes: final results". Respiratory Medicine. 87 (8): 621–23. doi:10.1016/S0954-6111(05)80265-3. PMID 8290746.
- Upadhyay SS, Saji MJ, Yau AC; Saji; Yau (August 1996). "Duration of antituberculosis chemotherapy in conjunction with radical surgery in the management of spinal tuberculosis". Spine. 21 (16): 1898–903. doi:10.1097/00007632-199608150-00014. PMID 8875723.
- Darbyshire, J.; Darbyshire, J (1999). "Five-year assessment of controlled trials of short-course chemotherapy regimens of 6, 9 or 18 months' duration for spinal tuberculosis in patients ambulatory from the start or undergoing radical surgery. Fourteenth report of the Medical Research Council Working Party on Tuberculosis of the Spine". International Orthopaedics. 23 (2): 73–81. doi:10.1007/s002640050311. PMC . PMID 10422019.
- Parthasarathy R, Sriram K, Santha T, Prabhakar R, Somasundaram PR, Sivasubramanian S; Sriram; Santha; Prabhakar; Somasundaram; Sivasubramanian (May 1999). "Short-course chemotherapy for tuberculosis of the spine. A comparison between ambulant treatment and radical surgery--ten-year report". The Journal of Bone and Joint Surgery. British Volume. 81 (3): 464–71. doi:10.1302/0301-620X.81B3.9043. PMID 10872368.
- Kent SJ, Crowe SM, Yung A, Lucas CR, Mijch AM (1993). "Tuberculous Meningitis: A 30-Year Review". Clin Infect Dis. 17 (6): 987–94. doi:10.1093/clinids/17.6.987. PMID 8110957.
- Teoh R, O'Mahony G, Yeung VT (1986). "Polymorphonuclear pleocytosis in the cerebrospinal fluid during chemotherapy for tuberculous meningitis". J Neurol. 233 (4): 237–41. doi:10.1007/BF00314027. PMID 3746363.
- Chang AB, et al. (1998). "Central nervous system tuberculosis after resolution of miliary tuberculosis". Pediatr Infect Dis J. 17 (6): 519–23. doi:10.1097/00006454-199806000-00019. PMID 9655548.
- Misra, U.K.; Kalita, J.; Nair, P.P. (2010). "Role of aspirin in tuberculous meningitis: a randomized open-label placebo-controlled trial". J Neurol Sci. 293: 12–17. doi:10.1016/j.jns.2010.03.025.
- "Tuberculous meningitis: take an aspirin and call me in the morning?". Clin Infect Dis. 51 (12): iv. 2010. doi:10.1086/657238.
- Thwaites GE, et al. (2004). "Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults". N Engl J Med. 351 (17): 1741–51. doi:10.1056/NEJMoa040573. PMID 15496623.
- Ordonez AA, Maiga M, Gupta S, Weinstein EA, Bishai WR, Jain SK (2014). "Novel adjunctive therapies for the treatment of tuberculosis". Current Molecular Medicine. 14 (3): 285–395. doi:10.2174/1566524013666131118112431. PMID 24236454.
- Roberts MT, Mendelson M, Meyer P, Carmichael A, Lever AM (2003). "The use of thalidomide in the treatment of intracranial tuberculomas in adults: two case reports". J Infect. 47 (3): 251–55. doi:10.1016/S0163-4453(03)00077-X. PMID 12963389.
- Purohit SD, Sarkar SK, Gupta ML, Jain DK, Gupta PR, Mehta YR (June 1987). "Dietary constituents and rifampicin absorption". Tubercle. 68 (2): 151–52. doi:10.1016/0041-3879(87)90034-1. PMID 3660467.
- Peloquin CA, Namdar R, Singleton MD, Nix DE (January 1999). "Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids". Chest. 115 (1): 12–18. doi:10.1378/chest.115.1.12. PMID 9925057.
- Siegler DI, Bryant M, Burley DM, Citron KM, Standen SM (July 1974). "Effect of meals on rifampicin absorption". Lancet. 2 (7874): 197–98. doi:10.1016/S0140-6736(74)91487-1. PMID 4135611.
- Peloquin CA, Namdar R, Dodge AA, Nix DE (August 1999). "Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids". The International Journal of Tuberculosis and Lung Disease. 3 (8): 703–10. PMID 10460103.
- Joshi MV, Saraf YS, Kshirsagar NA, Acharya VN (June 1991). "Food reduces isoniazid bioavailability in normal volunteers". The Journal of the Association of Physicians of India. 39 (6): 470–71. PMID 1938852.
- Zent C, Smith P (April 1995). "Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide". Tubercle and Lung Disease. 76 (2): 109–13. doi:10.1016/0962-8479(95)90551-0. PMID 7780091.
- Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, James GT, Nix DE (1998). "Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids". Pharmacotherapy. 18 (6): 1205–11. doi:10.1002/j.1875-9114.1998.tb03138.x. PMID 9855317.
- Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE (March 1999). "Pharmacokinetics of Ethambutol under Fasting Conditions, with Food, and with Antacids". Antimicrobial Agents and Chemotherapy. 43 (3): 568–72. PMC . PMID 10049268.
- Gallardo, CR; Rigau Comas, D; Valderrama Rodríguez, A; Roqué I Figuls, M; Parker, LA; Caylà, J; Bonfill Cosp, X (17 May 2016). "Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis.". The Cochrane database of systematic reviews. 5: CD009913. doi:10.1002/14651858.CD009913.pub2. PMC . PMID 27186634. Retrieved 6 June 2016.
- Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D (June 2003). "Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis". American Journal of Respiratory and Critical Care Medicine. 167 (11): 1472–77. doi:10.1164/rccm.200206-626OC. PMID 12569078.
- Ormerod LP, Horsfield N (February 1996). "Frequency and type of reactions to antituberculosis drugs: observations in routine treatment". Tubercle and Lung Disease. 77 (1): 37–42. doi:10.1016/S0962-8479(96)90073-8. PMID 8733412.
- Forget EJ, Menzies D (March 2006). "Adverse reactions to first-line antituberculosis drugs". Expert Opinion on Drug Safety. 5 (2): 231–49. doi:10.1517/14740318.104.22.168. PMID 16503745.
- Steele MA, Burk RF, DesPrez RM (February 1991). "Toxic hepatitis with isoniazid and rifampin. A meta-analysis". Chest. 99 (2): 465–71. doi:10.1378/chest.99.2.465. PMID 1824929.
- Hong Kong Chest Service Tuberculosis Research Centre, British Medical Research Council. (1989). "A controlleed trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum smear-negative pulmonary tuberculosis: results at 5 years". Am Rev Respir Dis. 139 (4): 871–76. doi:10.1164/ajrccm/139.4.871.
- Anderson L, Moore J, Kruijshaar M, et al. (November 2010). "Tuberculosis in the UK: Annual report on tuberculosis surveillance in the UK 2010". London: Tuberculosis Section, Health Protection Agency Centre for Infections. Retrieved 4 July 2011.
- O'Riordan P, Schwab U, Logan S, et al. (2008). Dheda K, ed. "Rapid Molecular Detection of Rifampicin Resistance Facilitates Early Diagnosis and Treatment of Multi-Drug Resistant Tuberculosis: Case Control Study". PLoS ONE. 3 (9): e3173. doi:10.1371/journal.pone.0003173. PMC . PMID 18779863.
- British Thoracic Association (1982). "A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. British Thoracic Association". Am Rev Respir Dis. 126 (3): 460–2. PMID 6751175.
- British Thoracic Society (1984). "A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society". Br J Dis Chest. 78 (4): 330–336. doi:10.1016/0007-0971(84)90165-7. PMID 6386028.
- British Thoracic Society (1988). "Short course chemotherapy for lymph node tuberculosis: final report at 5 years. British Thoracic Society Research Committee". Br J Dis Chest. 82 (3): 282–4. PMID 3073808.
- Slutkin G, Schecter GF, Hopewell PC (1988). "The results of 9-month isoniazid-rifampin therapy for pulmonary tuberculosis under program conditions in San Francisco". Am Rev Respir Dis. 138 (6): 1622–4. doi:10.1164/ajrccm/138.6.1622.
- American Thoracic Society/Centers for Disease Control and Prevention (1994). "Treatment of tuberculosis and tuberculosis infection in adults and children.". Am J Respir Crit Care Med. 149 (5): 1359–74. doi:10.1164/ajrccm.149.5.8173779.
- American Thoracic Society/Centers for Disease Control/Infectious Diseases Society of America (2003). "Treatment of tuberculosis.". MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 52 (RR-11): 1–77. PMID 12836625.
- Combs DL; O’Brien RJ; Geiter LJ (1990). "USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results". Ann Int Med. 112 (6): 397–406. doi:10.7326/0003-4819-76-3-112-6-397. PMID 2155569.
- Drobac PC, et al. (2005). "Treatment of Multidrug-Resistant Tuberculosis during Pregnancy: Long-Term Follow-Up of 6 Children with Intrauterine Exposure to Second-Line Agents". Clin Infect Dis. 40 (11): 1689–92. doi:10.1086/430066. PMID 15889370.[dead link]
- Palacios E, Dallman R, Muñoz M, et al. (2009). "Drug‐resistant tuberculosis and pregnancy: Treatment outcomes of 38 cases in Lima, Peru". Clin Infect Dis. 48 (10): 1413–19. doi:10.1086/598191. PMID 19361302.
- Breen RA, Miller RF, Gorsuch T, et al. (2006). "Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy". J Infect Dis. 193 (10): 1437–40. doi:10.1086/503437. PMID 16619192.
- Jenny‐Avital1 ER, Joseph K (2009). "Rifamycin‐resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: A report of 3 relapses with acquired rifampin resistance following alternate‐day rifabutin and boosted protease inhibitor therapy". Clin Infect Dis. 48 (10): 1471–74. doi:10.1086/598336. PMID 19368504.
- Dukes CS, Sugarman J, Cegielski JP, Lallinger GJ, Mwakyusa DH (1992). "Severe cutaneous hypersensitivity reactions during treatment of tuberculosis in patients with HIV infection in Tanzania". Trop Geogr Med. 44 (4): 308–11. PMID 1284179.
- Kuaban C, Bercion R, Koulla-Shiro S (1997). "HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon". East Afr Med J. 74 (8): 474–77. PMID 9487410.
- World Health Organisation. "WHO Global Task Force outlines measures to combat XDR-TB worldwide". Retrieved 2006-10-21.
- Centers for Disease Control and Prevention (2006). "Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second-Line Drugs — Worldwide, 2000–2004". MMWR Weekly. 55 (11): 301–05.
- Sarah McGregor. "New TB strain could fuel South Africa AIDS toll". Reuters. Retrieved 2006-09-17.
- Frieden TR, Sterling T, Pablos-Mendez A, et al. (1993). "The emergence of drug-resistant tuberculosis in New York City". N Engl J Med. 328 (8): 521–56. doi:10.1056/NEJM199302253280801. PMID 8381207.
- Laurie Garrett (2000). Betrayal of trust: the collapse of global public health. New York: Hyperion. p. 268ff. ISBN 9780786884407.
- Farmer Paul (2001). "The Major Infectious Diseases in the World -- To Treat or Not to Treat?". N Engl J Med. 345 (3): 208–210. doi:10.1056/nejm200107193450310.
- Salazar-Austin N, Ordonez AA, Hsu AJ, et al. (2015). "Extensively drug-resistant tuberculosis in a young child after travel to India". The Lancet Infectious Diseases. 15 (12): 1485–1491. doi:10.1016/S1473-3099(15)00356-4. PMID 26607130.
- Shah NS, Wright A, Drobniewski F, et al. (2005). "Extreme drug resistance in tuberculosis (XDR-TB): global survey of supranational reference laboratories for _Mycobacterium tuberculosis_ with resistance to second-line drugs". Int J Tuberc Lung Dis. 9 (Suppl 1): S77.
- Centers for Disease Control and Prevention (2006). "Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second-Line Drugs — Worldwide, 2000–2004". MMWR Weekly. 55 (11): 301–05.
- Gandhi NR, Moll A, Sturm AW, et al. (2006). "Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa". Lancet. 368 (9547): 1575–80. doi:10.1016/S0140-6736(06)69573-1. PMID 17084757.
- Angela Quintal. "314 XDR-TB cases reported in SA". Cape Times. Retrieved 2007-04-04.
- Migliori GB, Ortmann J, Girardi E, et al. (2007). "Extensively Drug-resistant Tuberculosis, Italy and Germany". Emerging Infectious Diseases. 13 (5): 780–82. doi:10.3201/eid1305.070200. PMC . PMID 18044040.
- Sidley P. (2006). "South Africa acts to curb spread of lethal strain of TB". Brit Med J. 333 (7573): 825. doi:10.1136/bmj.333.7573.825-a. PMC . PMID 17053232.
- News24. "300+ cases of killer TB in SA". Retrieved 2006-11-23.
- Singh JA, Upshur R, Padayatchi N (2007). "XDR-TB in South Africa: No Time for Denial or Complacency". PLoS Med. 4 (1): e50. doi:10.1371/journal.pmed.0040050. PMC . PMID 17253901.
- Orenstein EW, Basu S, Shah NS, et al. (2009). "Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis". Lancet Infect Dis. 9 (3): 153–61. doi:10.1016/S1473-3099(09)70041-6. PMID 19246019.
- Mitnick C, et al. (2003). "Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru". N Engl J Med. 348 (2): 119–28. doi:10.1056/NEJMoa022928. PMID 12519922.
- Gillespie SH (2002). "Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective". Antimicrob Agents Chemother. 46 (2): 267–74. doi:10.1128/AAC.46.2.267-274.2002. PMC . PMID 11796329.
- Bang D, Andersen Å, Thomsen V (2006). "Rapid Genotypic Detection of Rifampin- and Isoniazid-Resistant Mycobacterium tuberculosis Directly in Clinical Specimens". J Clin Microbiol. 44 (7): 2605–08. doi:10.1128/JCM.00752-06. PMC . PMID 16825393.
- Aktas E, Durmaz R, Yang D, Yang Z (2005). "Molecular characterization of isoniazid and rifampin resistance of Mycobacterium tuberculosis clinical isolates from Malatya, Turkey". Microbial Drug Resistance. 11 (2): 94–99. doi:10.1089/mdr.2005.11.94. PMID 15910221.
- Steering Group; Ernesto Jaramillo... (2008). Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008 (WHO/HTM/TB/2008.402). Geneva, Switzerland: World Health Organization. p. 51. ISBN 9789241547581.
- Reljic R (2007). "IFN-gamma therapy of tuberculosis and related infections". J Interferon Cytokine Res. 27 (5): 353–64. doi:10.1089/jir.2006.0103. PMID 17523867.
- "Old drug combination in TB fight". BBC News. 27 February 2009. Retrieved 27 February 2009.
- Dauby N, Muylle I, Mouchet F, Sergysels R, Payen MC (2011). "Meropenem/Clavulanate and Linezolid Treatment for Extensively Drug-Resistant Tuberculosis". Pediatric Infectious Disease Journal. 30 (9): 812–3. doi:10.1097/INF.0b013e3182154b05. PMID 21378593.
- Ziganshina LE, Vizel AA, Squire SB. (2005). Ziganshina, Lilia, ed. "Fluoroquinolones for treating tuberculosis". Cochrane Database of Systematic Reviews (3): CD004795. doi:10.1002/14651858.CD004795.pub2. PMID 16034951.
- Leimane V, et al. (2005). "Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study". Lancet. 365 (9456): 318–26. doi:10.1016/S0140-6736(05)17786-1. PMID 15664227.
- Schön T, Elias D, Moges F, et al. (2003). "Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis". Eur Respir J. 21 (3): 483–88. doi:10.1183/09031936.03.00090702. PMID 12662006.
- Rockett KA, Brookes R, Udalova I, et al. (November 1, 1998). "1,25-Dihydroxyvitamin D3 Induces Nitric Oxide Synthase and Suppresses Growth of Mycobacterium tuberculosis in a Human Macrophage-Like Cell Line". Infection and Immunity. 66 (11): 5314–21. PMC . PMID 9784538.
- Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC (2005). "Imipenem for Treatment of Tuberculosis in Mice and Humans". Antimicrob Agents Chemother. 49 (7): 2816–21. doi:10.1128/AAC.49.7.2816-2821.2005. PMC . PMID 15980354.
- Chambers HF, Kocagoz T, Sipit T, Turner J, Hopewell PC (1998). "Activity of amoxicillin/clavulanate in patients with tuberculosis". Clin Infect Dis. 26 (4): 874–77. doi:10.1086/513945. PMID 9564467.
- Donald PR, Sirgel FA, Venter A, et al. (2001). "Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis". Scand J Infect Dis. 33 (6): 466–69. doi:10.1080/00365540152029954. PMID 11450868.
- Jagannath C, Reddy MV, Kailasam S, O'Sullivan JF, Gangadharam PR (April 1, 1995). "Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies". Am J Respir Crit Care Med. 151 (4): 1083–86. doi:10.1164/ajrccm.151.4.7697235. PMID 7697235.
- Adams LM, Sinha I, Franzblau SG, et al. (1999). "Effective Treatment of Acute and Chronic Murine Tuberculosis with Liposome-Encapsulated Clofazimine" (PDF). Antimicrob Agents Chemother. 43 (7): 1638–43. PMC . PMID 10390215.
- Janulionis, E.; Sofer, C; Song, HY; Wallis, RS (2004). "Lack of Activity of Orally Administered Clofazimine against Intracellular Mycobacterium tuberculosis in Whole-Blood Culture" (PDF). Antimicrob Agents Chemother. 48 (8): 3133–35. doi:10.1128/AAC.48.8.3133-3135.2004. PMC . PMID 15273133.
- Shubin H; Sherson J; Pennes E; Glaskin A; Sokmensuer A. (1958). "Prochlorperazine (compazine) as an aid in the treatment of pulmonary tuberculosis". Antibiotic Med Clin Ther. 5 (5): 305–09. PMID 13521769.
- Wayne LG, Sramek HA (1994). "Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis". Antimicrob Agents Chemother. 38 (9): 2054–58. doi:10.1128/AAC.38.9.2054. PMC . PMID 7811018.
- "FDA Press Release". U.S. Food and Drug Administration. 31 December 2012.
- Carroll, John (31 December 2012). "J&J wins accelerated OK for first new TB drug in 40 years". fiercebiotech.com. Retrieved 3 January 2013.
- Stover CK, Warrener P, VanDevanter DR, et al. (2000). "A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis". Nature. 405 (6789): 962–66. doi:10.1038/35016103. PMID 10879539.
- Chase, Marilyn (27 October 2004). "Novartis Sets Deal to Seek New Drugs for Fighting TB". The Wall Street Journal. Retrieved 3 January 2013.
- Anurag Bhargava; Lancelot Pinto; Madhukar Pai (2011). "Mismanagement of tuberculosis in India: Causes, consequences, and the way forward". Hypothesis. 9 (1): e7. doi:10.5779/hypothesis.v9i1.214.
- Harries AD; Hargreaves NJ, Kumwenda J, Kwanjana1 JH, Salaniponi1 FM (2000). "Trials of anti-tuberculosis treatment in areas of high human immunodeficiency virus prevalence in sub-Saharan Africa". Int J Tuberc Lung Dis. 4 (11): 998–1001. PMID 11092710.
- Fourie B, Weyer K (2000). "Trials of anti-tuberculosis treatment as a diagnostic tool in smear-negative tuberculosis are of questionable benefit". Int J Tuberc Lung Dis. 4 (11): 997. PMID 11092709.
- Chan ED, Laurel V, Strand MJ, et al. (2004). "Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis". Am J Respir Crit Care Med. 169 (10): 1103–09. doi:10.1164/rccm.200308-1159OC. PMID 14742301.
- van Leuven M, De Groot M, Shean KP, von Oppell UO, Willcox PA (1997). "Pulmonary resection as an adjunct in the treatment of multiple drug-resistant tuberculosis". Ann Thorac Surg. 63 (5): 1368–72. doi:10.1016/s0003-4975(97)80353-0. PMID 9146329.
- Sung SW, Kang CH, Kim YT, Han SK, Shim YS, Kim JH (1999). "Surgery increased the chance of cure in multi-drug resistant pulmonary tuberculosis". Eur J Cardiothorac Surg. 16 (2): 187–93. doi:10.1016/S1010-7940(99)00158-X. PMID 10485419.
- Pomerantz BJ, Cleveland JC Jr, Olson HK, Pomerantz M (2001). "Pulmonary resection for multi-drug resistant tuberculosis". J Thorac Cardiovasc Surg. 121 (3): 448–53. doi:10.1067/mtc.2001.112339. PMID 11241079.
- Park SK, Lee CM, Heu JP, Song SD (2002). "A retrospective study for the outcome of pulmonary resection in 49 patients with multidrug-resistant tuberculosis". Int J Tuberc Lung Dis. 6 (2): 143–49. PMID 11931413.
- Naidoo R, Reddi A (2005). "Lung resection for multidrug-resistant tuberculosis". Asian Cardiovasc Thorac Ann. 13 (2): 172–74. doi:10.1177/021849230501300216. PMID 15905349.
- Shiraishi Y, Nakajima Y, Katsuragi N, Kurai M, Takahashi N (2004). "Resectional surgery combined with chemotherapy remains the treatment of choice for multidrug-resistant tuberculosis". J Thorac Cardiovasc Surg. 128 (4): 523–28. doi:10.1016/j.jtcvs.2004.06.012. PMID 15457152.
- Li WT, Jiang GN, Gao W, Xiao HP, Ding JA (2006). "Surgical treatment of multi-drug resistant pulmonary tuberculosis in 188 cases 耐多藥肺結核188例的外科治療". Chinese Journal of Tuberculosis and Respiratory Diseases 中華結核和呼吸雜誌 (in Chinese). 29 (8): 524–26. PMID 17074264. External link in
- Mohsen T, Zeid AA, Haj-Yahia S (2007). "Lobectomy or pneumonectomy for multidrug-resistant pulmonary tuberculosis can be performed with acceptable morbidity and mortality: A seven-year review of a single institution's experience". J Thorac Cardiovasc Surg. 134 (1): 194–98. doi:10.1016/j.jtcvs.2007.03.022. PMID 17599508.
- Cegielski JP, McMurray DN (2004). "The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals". Int J Tubercul Lung Dis. 8 (3): 286–98.
- Onwubalili JK. (1988). "Malnutrition among tuberculosis patients in Harrow, England". Eur J Clin Nutr. 42 (4): 363–66. PMID 3396528.
- Karyadi E, Schultink W, Nelwan RH, et al. (2000). "Poor Micronutrient Status of Active Pulmonary Tuberculosis Patients in Indonesia". J Nutrition. 130: 2953–58.
- Zachariah R, Spielmann MP, Harries AD, Salaniponi FM (2002). "Moderate to severe malnutrition in patients with tuberculosis is a risk factor associated with early death". Trans R Soc Trop Med Hyg. 96 (3): 291–94. doi:10.1016/S0035-9203(02)90103-3. PMID 12174782.
- Baldwin M; Yori, PP; Ford, C; Moore, DA; Gilman, RH; Vidal, C; Ticona, E; Evans, CA (2004). "Tuberculosis and nutrition: disease perceptions and health seeking behavior of household contacts in the Peruvian Amazon". Int J Tuberc Lung Dis. 8 (12): 1484–91. PMC . PMID 15636496.
- Nnoaham KE, Clarke A (2008). "Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis". Int J Epidemiol. 37 (1): 113–19. doi:10.1093/ije/dym247. PMID 18245055.
- Davies PD (1985). "A possible link between vitamin D deficiency and impaired host defence to Mycobacterium tuberculosis". Tubercle. 66 (4): 301–06. doi:10.1016/0041-3879(85)90068-6. PMID 3936248.
- Vieth R (2011). "Vitamin D nutrient to treat TB begs the prevention question". Lancet. 377 (9761): 189, 190. doi:10.1016/S0140-6736(10)62300-8.
- Liu PT, Stenger S, Li H, et al. (2006). "Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response". Science. 311 (5768): 1770–73. doi:10.1126/science.1123933. PMID 16497887.
- Finsen NR (1886). Om anvendelse i medicinen af koncentrerede kemiske lysstraaler. Copenhagen, Denmark: Gyldendalske Boghandels Forlag.
- Brodie MJ, Boobis AR, Hillyard CJ, Abeyasekera G, MacIntyre I, Park BK (1981). "Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity". Clin Pharmacol Ther. 30 (3): 363–67. doi:10.1038/clpt.1981.173. PMID 7273600.
- Brodie MJ, Boobis AR, Hillyard CJ, et al. (1982). "Effect of rifampicin and isoniazid on vitamin D metabolism". Clin Pharmacol Ther. 32 (4): 525–30. doi:10.1038/clpt.1982.197. PMID 7116768.
- Perry W, Erooga MA, Brown J, Stamp TC (1982). "Calcium metabolism during rifampicin and isoniazid therapy for tuberculosis". J R Soc Med. 75 (7): 533–36. PMC . PMID 7086805.
- Williams SE, Wardman AG, Taylor GA, Peacock M, Cooke NJ (1985). "Long term study of the effect of rifampicin and isoniazid on vitamin D metabolism". Tubercle. 66 (1): 49–54. doi:10.1016/0041-3879(85)90053-4. PMID 3838603.
- Chan TY (1996). "Osteomalacia during rifampicin and isoniazid therapy is rare in Hong Kong". Int J Clin Pharmacol Ther. 34 (12): 533–34. PMID 8996847.
- Bellamy R, Ruwende C, Corrah T, et al. (1998). "Tuberculosis and chronic hepatitis B virus infection in africans and variation in the vitamin D receptor gene". J Infect Dis. 179 (3): 721–24. doi:10.1086/314614. PMID 9952386.
- Wilkinson R, Llewelyn M, Toossi Z, et al. (2000). "Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study". Lancet. 355 (9204): 618–21. doi:10.1016/S0140-6736(99)02301-6. PMID 10696983.
- 刘玮,张翠英,吴晓明; et al. (2003). "维生素D受体基因多态性与肺结核易感性的病例对照研究 (A case-control study on the vitamin D receptor gene polymorphisms and susceptibility to pulmonary tuberclosis)". 中华流行病学杂志 (Chinese Journal of Epidemiology) (in Chinese). 24 (5): 389–92. PMID 12820934.
- Martineau AR, Timms PM, Bothamley GH, et al. (2011). "High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial". Lancet. 377 (9761): 242–50. doi:10.1016/S0140-6736(10)61889-2. PMID 21215445.
- Daley P, Jagannathan V, John KR, et al. (2015). "Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial.". Lancet Infect Dis. 15: 528–34. doi:10.1016/S1473-3099(15)70053-8. PMID 25863562.
- Wejse C, Gomes VF, Rabna P, et al. (2009). "Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial". Am J Respir Crit Care Med. 179 (9): 843–50. doi:10.1164/rccm.200804-567OC. PMID 19179490.
- Cegielski P, Vernon A (2015). "Tuberculosis and vitamin D: what's the rest of the story?". Lancet Infect Dis. 15: 489–90. doi:10.1016/S1473-3099(15)70163-5. PMID 25863560.
- Williams, C. J. B. (1849). "Cod liver oil in phthisis". London J Med. 1: 1–18. doi:10.1136/bmj.s2-1.1.1.
- Spector SA (2009). "Vitamin D earns more than a passing grade". J Infect Dis. 200 (7): 1015–17. doi:10.1086/605723. PMID 19673648.
- Martineau AR, Wilkinson RJ, Wilkinson KA, Newton SM, Kampmann B, Hall BM, et al. (2007). "A single dose of vitamin D enhances immunity to Mycobacteria". Am J Respir Crit Care Med. 176 (2): 208–13. doi:10.1164/rccm.200701-007OC. PMID 17463418.
- Rook GA, Steele J, Fraher L, et al. (1986). "Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes". Immunology. 57 (1): 159–63. PMC . PMID 3002968.
- Crowle AJ, Ross EJ, May MH (1987). "Inhibition by 1,25(OH)2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages". Infection and Immunity. 55 (12): 2945–50. PMC . PMID 3119492.
- Sly M, Lopez M, Nauseef WM, Reiner NE (2001). "1α,25-dihydroxyvitamin D3-induced monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by the NADPH-dependent phagocyte oxidase". J Biol Chem. 276 (38): 35482–93. doi:10.1074/jbc.M102876200. PMID 11461902.
- Martineau AR, Wilkinson KA, Newton SM, et al. (2007). "IFN-γ- and TNF-independent vitamin D-inducible human suppression of mycobacteria: The role of cathelicidin LL-37". Journal of Immunology. 178: 7190–98. doi:10.4049/jimmunol.178.11.7190.
- Coussens A, Timms PM, Boucher BJ, et al. (2009). "1α,25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium tuberculosis infection". Immunology. 127 (4): 539–48. doi:10.1111/j.1365-2567.2008.03024.x. PMC . PMID 19178594.
- Schechter M, Zajdenverg R, Falco G, Barnes G, Faulhaber J, Coberly J, Moore R, Chaisson R (2006). "Weekly Rifapentine/Isoniazid or Daily Rifampin/Pyrazinamide for Latent Tuberculosis in Household Contacts". Am J Respir Crit Care Med. 173 (8): 922–26. doi:10.1164/rccm.200512-1953OC. PMC . PMID 16474028.
- Ijaz K, Jereb JA, Lambert LA, et al. (2006). "Severe of fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis". Clin Infect Dis. 42 (3): 346–55. doi:10.1086/499244. PMID 16392079.
- Smieja M. J.; Marchetti C. A.; Cook D. J.; Smaill F. M. (2000). "Isoniazid for preventing tuberculosis in non-HIV infected persons". Cochrane Database of Systematic Reviews. 2: CD001363. doi:10.1002/14651858.CD001363. PMID 10796642.
- Sharma SK, Sharma A, Kadhiravan T, Tharyan P (2013). "Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB". Cochrane Database Syst Rev. 7: CD007545. doi:10.1002/14651858.CD007545.pub2. PMID 23828580.
- Stagg HR, Zenner D, Harris RJ, Muñoz L, Lipman MC, Abubakar I (August 2014). "Treatment of Latent Tuberculosis Infection: A Network Meta-analysis". Ann. Intern. Med. Online first (6): 419–28. doi:10.7326/M14-1019. PMID 25111745.
- Nuermberger EL, Yoshimatsu T, Tyagi S, et al. (2004). "Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine Tuberculosis". Am J Respir Crit Care Med. 169 (3): 421–26. doi:10.1164/rccm.200310-1380OC. PMID 14578218.
- Gosling RD, Uiso LO, Sam NE, et al. (2003). "The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis". Am J Respir Crit Care Med. 168 (11): 1342–45. doi:10.1164/rccm.200305-682OC. PMID 12917230.
- Nuermberger EL, Yoshimatsu T, Tyagi S, et al. (2004). "Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis". Am J Respir Crit Care Med. 170 (10): 1131–34. doi:10.1164/rccm.200407-885OC. PMID 15306535.
- TB Alliance. "TB Alliance and Bayer launch historic global TB drug trials". Archived from the original on September 25, 2006. Retrieved 2006-10-17.
- Lienhardta C, Vernonb A, Raviglionec MC (2010). "New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes" (PDF). Current Opinion in Pulmonary Medicine. 16: 186–93. This article incorporates public domain material from websites or documents of the Centers for Disease Control and Prevention.